


Stabilis



Heparin sodium



Noms commerciaux

Arapin	Chili
Ateroclar	Italie
Clarisco	Italie
Epsoclar	Italie
Hepaflex	Finlande, Norvège
Hepamax	Chili, Colombie, Equateur
Heparin	Afrique du sud, Autriche, Canada, Danemark, Etats Unis d'Amérique, Finlande, Grande Bretagne, Grèce, Hongrie, Norvège, Pays bas, Russie, Serbie, Suède, Suisse, Thaïlande, Turquie
Heparine	Belgique, France
Heparinised	Australie
Heparstad	Allemagne
Liquemin	Suisse, Turquie
Liquemine	Brésil
Monoparin	Arabie Saoudite
Normoparin	Italie
Nuparin	Equateur
Pharepa	Italie
Riveparin	Argentine
Sobrius	Argentine, Equateur
Thrombophob	Allemagne



Stabilité des solutions

Icon 1	Icon 2	Icon 3	Icon 4	Icon 5	Icon 6	Icon 7	Icon 8	Icon 9
		1 UI/ml	25°C		365			4166
		1 UI/ml	20°C-25°C		365			1291
		10 UI/ml	20°C-25°C		365			1291
		7 UI/ml	22°C		24			1067
		7 UI/ml	4°C		24			1067
		1 UI/ml	20°C		365			1234
		1 UI/ml	37°C		365			1234

		100 UI/ml	4°C		14			895
		500 UI/ml	25°C		21			1183
		500 UI/ml	4°C		21			1183
		1000 & 40000 UI/ml	30°C		30			874
		5000 UI/ml	4°C		28			791



Stabilité en mélange

		9,75 UI/ml	23°C		Vancomycin hydrochloride : 0,025 mg/ml	85		3958
		50 UI/ml	25°C		Magnesium sulfate : 15,6 mg/ml	14		2100
		2500 UI/ml	37°C		Telavancin hydrochloride : 2 & 5 mg/ml Sodium citrate : 22 & 40 mg/ml	72		3327
		2500 UI/ml	37°C		Vancomycin hydrochloride : 2 & 5 mg/ml Sodium citrate : 22 & 40 mg/ml	72		3327
		100 UI/ml	4°C		Vancomycin hydrochloride : 0,025 mg/ml	63		1414
		9,75 UI/ml	4°C		Vancomycin hydrochloride : 0,025 mg/ml	85		3958
		59 UI/ml	22°C-23°C		Milrinone lactate : 0,2 mg/ml	4		813
		20 UI/ml	23°C-25°C		Dopamine hydrochloride : 0,8 mg/ml	24		738
		50 UI/ml	25°C		Palonosetron hydrochloride : 25 µg/ml	4		2279
		100 UI/ml	25°C		Fluconazole : 1 mg/ml	24		257
		20 & 50 UI/ml	25°C		Tirofiban : 25 µg/ml	4		1420
		50 UI/ml	23°C		Flumazenil : 0,02 mg/ml	24		187
		0,5 UI/ml	37°C		Piperacillin sodium / tazobactam : 0,5/0,0625 mg/ml	168		4180
		0,5 UI/ml	37°C		Meropenem : 0,5 mg/ml	10		4180
		0,5 UI/ml	4°C		Piperacillin sodium / tazobactam : 0,5/0,0625 mg/ml	168		4180
		0,5 UI/ml	4°C		Meropenem : 0,5 mg/ml	168		4180
		0,5 UI/ml	37°C		Piperacillin sodium / tazobactam : 0,5/0,0625 mg/ml	168		4180
		0,5 UI/ml	37°C		Meropenem : 0,5 mg/ml	10		4180
		0,5 UI/ml	37°C		Ceftazidime : 0.125 mg/ml	12		4056
		0,5 UI/ml	4°C		Ceftazidime : 0.125 mg/ml	120		4056
		0,5 UI/ml	4°C		Piperacillin sodium / tazobactam : 0,5/0,0625 mg/ml	168		4180
		0,5 UI/ml	4°C		Meropenem : 0,5 mg/ml	168		4180
		0,5 UI/ml	37°C		Piperacillin sodium / tazobactam : 0,5/0,0625 mg/ml	168		4180

PVC		0,5 UI/ml	37°C	?	Meropenem : 0,5 mg/ml	10		4180
PVC		0.5 UI/ml	37°C	?	Ceftazidime : 0.125 mg/ml	12		4056
PVC		0.5 UI/ml	4°C	?	Ceftazidime : 0.125 mg/ml	120		4056
PVC		0,5 UI/ml	4°C	?	Piperacillin sodium / tazobactam : 0,5/0,0625 mg/ml	168		4180
PVC		0,5 UI/ml	4°C	?	Meropenem : 0,5 mg/ml	168		4180
PVC		0,5 UI/ml	37°C	?	Piperacillin sodium / tazobactam : 0,5/0,0625 mg/ml	168		4180
PVC		0,5 UI/ml	37°C	?	Meropenem : 0,5 mg/ml	10		4180
PVC		0.5 UI/ml	37°C	?	Ceftazidime : 0.125 mg/ml	12		4056
PVC		0.5 UI/ml	4°C	?	Ceftazidime : 0.125 mg/ml	120		4056
PVC		0,5 UI/ml	4°C	?	Piperacillin sodium / tazobactam : 0,5/0,0625 mg/ml	168		4180
PVC		0,5 UI/ml	4°C	?	Meropenem : 0,5 mg/ml	168		4180
PVC		1,4 UI/ml	37°C	?	Piperacillin sodium / tazobactam : 1,38/0,172 mg/ml	168		4180
PVC		1,4 UI/ml	4°C	?	Piperacillin sodium / tazobactam : 1,38/0,172 mg/ml	168		4180
PVC		1,4 UI/ml	37°C	?	Piperacillin sodium / tazobactam : 1,38/0,172 mg/ml	168		4180
PVC		1,4 UI/ml	4°C	?	Piperacillin sodium / tazobactam : 1,38/0,172 mg/ml	168		4180
PVC		1,4 UI/ml	37°C	?	Piperacillin sodium / tazobactam : 1,38/0,172 mg/ml	168		4180
PVC		1,4 UI/ml	4°C	?	Piperacillin sodium / tazobactam : 1,38/0,172 mg/ml	168		4180
PP		5000 UI/ml	4°C	?	Vancomycin hydrochloride : 0,1 mg/ml	28		3956
PP		5000 UI/ml	4°C	?	Gentamicin sulfate : 0,1 mg/ml	28		3956
PP		100 UI/ml	4°C		Vancomycin hydrochloride : 0,025 mg/ml	14		895
PP	RL	100 UI/ml	-20°C		Daptomycin : 5 mg/ml	14		3665
PP	RL	100 UI/ml	4°C	?	Daptomycin : 5 mg/ml	14		3665
PP	∅	960 UI/ml	37°C	?	Fluorouracil : 24 mg/ml	7		163
PP	∅	960 UI/ml	4°C		Fluorouracil : 24 mg/ml	14		163
?		5000 UI/ml	22°C-28°C	?	Daptomycin : 19,6 mg/ml	2		1937


























































Facteur influençant la stabilité

				1415
				1391
				1183
	PVC			1468



Compatibilités

				
		Heparin sodium : 50 UI/ml Aciclovir sodium : 5 mg/ml		336
		Heparin sodium : 100 UI/ml Aciclovir sodium : 5 mg/ml		2335
		Heparin sodium : 100 UI/ml Aldesleukin : 0.0338 MUI/ml		36
		Heparin sodium : 100 UI/ml Allopurinol sodium : 3 mg/ml		307
		Heparin sodium : 1 UI/ml Alprostadil : 20 µg/ml		4651
		Heparin sodium : 1 UI/ml Alprostadil : 20 µg/ml		4491
		Heparin sodium : 40 UI/ml Alteplase : 0.5 mg/ml		240
		Heparin sodium : 100 UI/ml Alteplase : 1 mg/ml		92
		Heparin sodium Alteplase		3540
		Heparin sodium Alteplase		3616
		Heparin sodium : 100 UI/ml Amifostine : 10 mg/ml		3
		Heparin sodium Amikacin sulfate		3540
		Heparin sodium Amikacin sulfate		1022
		Heparin sodium Amikacin sulfate		3549
		Heparin sodium Amiodarone hydrochloride		3540
		Heparin sodium : 500 UI/ml Amiodarone hydrochloride : 15 mg/ml		3463
		Heparin sodium Amiodarone hydrochloride		3464
		Heparin sodium : 500 UI/ml Amiodarone hydrochloride : 15 mg/ml		3823
		Heparin sodium : 208 UI/ml Amoxicillin sodium : 20.83 & 83.3 mg/ml		4254
		Heparin sodium : 1000 UI/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
		Heparin sodium : 1000 UI/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
		Heparin sodium : 50 UI/ml Ampicillin sodium : 20 mg/ml		317
		Heparin sodium : 10 & 5000 UI/ml Ampicillin sodium : 10 mg/ml		2037
		Heparin sodium Ampicillin sodium		3540

		Heparin sodium : 50 UI/ml Ampicillin sodium - sulbactam sodium : 30 mg/ml	∅	317
		Heparin sodium : 40 UI/ml Amsacrine : 1 mg/ml	◆	253
		Heparin sodium : 100 UI/ml Anidulafungin : 0.5 mg/ml	◆	1982
		Heparin sodium : 2 & 100 UI/ml Antithymocyte globulin (rabbit) : 0,2 & 0,3 mg/ml	▲	1822
		Heparin sodium : 100 UI/ml Antithymocyte globulin (rabbit) : 0,2 & 0,3 mg/ml	◆	1822
		Heparin sodium : 2 UI/ml Antithymocyte globulin (rabbit) : 0,2 & 0,3 mg/ml	◆	1822
		Heparin sodium : 40 UI/ml Atracurium besylate : 0.5 mg/ml	◆	402
		Heparin sodium : 1 UI/ml Atropine sulfate : 0.5 mg/ml	▲◆	1228
		Heparin sodium : 1 UI/ml Atropine sulfate : 0.5 mg/ml	RL	1228
		Heparin sodium : 50 UI/ml Aztreonam : 20 mg/ml	∅	317
		Heparin sodium : 100 UI/ml Aztreonam : 40 mg/ml	◆	99
		Heparin sodium : 1 UI/ml Betamethasone sodium phosphate : 3 mg/ml	RL	1228
		Heparin sodium : 1 UI/ml Betamethasone sodium phosphate : 3 mg/ml	▲◆	1228
		Heparin sodium : 100 UI/ml Bivalirudin : 5 mg/ml	◆	1713
		Heparin sodium : 192.3 UI/ml Blinatumomab : 0.125 & 0.375 µg/ml	▲	3976
		Heparin sodium : 1000 UI/ml Caffeine : 10 mg/ml	∅	3964
		Heparin sodium : 2 UI/ml Calcium chloride : 20 mg/ml	◆	4732
		Heparin sodium Calcium chloride		1084
		Heparin sodium : 100 UI/ml Calcium chloride : 20 mg/ml	◆	4732
		Heparin sodium Calcium gluconate		1084
		Heparin sodium : 100 UI/ml Caspofungin acetate : 0,7 mg/ml	▲	2247
		Heparin sodium : 100 UI/ml Caspofungin acetate : 0.5 mg/ml	▲	2233
		Heparin sodium Cefalotin sodium		3540
		Heparin sodium : 0.667 UI/ml Cefazolin sodium : 0.333 mg/ml		1979
		Heparin sodium : 50 UI/ml Cefazolin sodium : 20 mg/ml	∅	317
		Heparin sodium : 10 & 5000 UI/ml Cefazolin sodium : 10 mg/ml	▲	2037

		Heparin sodium : 10 & 50 UI/ml Cefepime dihydrochloride : 4 mg/ml		3548
		Heparin sodium : 1000 UI/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Heparin sodium : 100 UI/ml Cefmetazole sodium : 100 mg/ml		93
		Heparin sodium : 5000 UI/ml Cefotaxime sodium : 10 mg/ml		3125
		Heparin sodium : 208 UI/ml Cefotaxime sodium : 41.6 & 125 mg/ml		4254
		Heparin sodium : 100 UI/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
		Heparin sodium : 100 UI/ml Ceftaroline fosamil : 2,22 mg/ml		3249
		Heparin sodium : 0.5 UI/ml Ceftazidime : 0.125 mg/ml		4056
		Heparin sodium : 0.5 UI/ml Ceftazidime : 0.125 mg/ml		4056
		Heparin sodium : 0.5 UI/ml Ceftazidime : 0.125 mg/ml		4056
		Heparin sodium : 50 UI/ml Ceftazidime : 20 mg/ml	∅	317
		Heparin sodium : 100 UI/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269
		Heparin sodium : 100 UI/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
		Heparin sodium : 1000 UI/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Heparin sodium : 50 UI/ml Ceftriaxone disodium : 20 mg/ml	∅	317
		Heparin sodium : 10 & 50 UI/ml Cefuroxime sodium		3687
		Heparin sodium : 1 UI/ml Chlorpromazine hydrochloride : 10 mg/ml	RL	1228
		Heparin sodium : 1 UI/ml Chlorpromazine hydrochloride : 10 mg/ml		1228
		Heparin sodium Chlorpromazine hydrochloride		3540
		Heparin sodium : 58,34 UI/ml Chlorpromazine hydrochloride : 0,26 mg/ml		1289
		Heparin sodium : 50 UI/ml Cimetidine hydrochloride : 6 mg/ml	∅	317
		Heparin sodium : 10 UI/ml Ciprofloxacin lactate : 2 mg/ml	∅	1393
		Heparin sodium : 10 >> 10000 UI/ml Ciprofloxacin lactate : 0.1 mg/ml		2057
		Heparin sodium : 1000 >> 10000 UI/ml Ciprofloxacin lactate : 0.2 mg/ml		2057
		Heparin sodium : 10 >> 1000 UI/ml Ciprofloxacin lactate : 2 mg/ml		289
		Heparin sodium : 5000 & 10000 UI/ml Ciprofloxacin lactate : 0.4 & 0.6 mg/ml		2057

		Heparin sodium : 10000 UI/ml Ciprofloxacin lactate : 0.8 mg/ml		2057
		Heparin sodium : 10 >> 10000 UI/ml Ciprofloxacin lactate : 1 mg/ml		2057
		Heparin sodium : 100 UI/ml Ciprofloxacin lactate : 2 mg/ml		288
		Heparin sodium Ciprofloxacin lactate		3529
		Heparin sodium : 10 >> 1000 UI/ml Ciprofloxacin lactate : 0.4 & 0.6 mg/ml		2057
		Heparin sodium : 10 & 100 UI/ml Ciprofloxacin lactate : 0.2 mg/ml		2057
		Heparin sodium Ciprofloxacin lactate		3540
		Heparin sodium : 10 >> 5000 UI/ml Ciprofloxacin lactate : 0.8 mg/ml		2057
		Heparin sodium : 100 UI/ml Cisatracurium besylate : 5 mg/ml		299
		Heparin sodium : 100 UI/ml Cisatracurium besylate : 0.1 & 2 mg/ml		299
		Heparin sodium : 500 UI/ml Cisatracurium besylate : 5 mg/ml		3463
		Heparin sodium : 500 UI/ml Cisatracurium besylate : 5 mg/ml		3823
		Heparin sodium Cisatracurium besylate		3540
		Heparin sodium : 100 UI/ml Cladribine : 0.5 mg/ml		1496
		Heparin sodium : 50 UI/ml Clonidine hydrochloride : 0.0075 mg/ml		1506
		Heparin sodium : 1 UI/ml Cyanocobalamine : 0.1 mg/ml	RL	1228
		Heparin sodium : 1000 UI/ml	RL	4603
		Heparin sodium : 1 UI/ml Cyanocobalamine : 0.1 mg/ml		1228
		Heparin sodium Cytarabine		3540
		Heparin sodium : 100 UI/ml Dacarbazine : 25 mg/ml		860
		Heparin sodium Dacarbazine		3540
		Heparin sodium Daptomycin		2271
		Heparin sodium : 98 UI/ml Daptomycin : 19,6 mg/ml		1937
		Heparin sodium Daunorubicin hydrochloride		3540
		Heparin sodium Daunorubicin hydrochloride liposome		3577
		Heparin sodium : 373 UI/ml Defibrotide : 8 mg/ml		3728

		Heparin sodium : 50 UI/ml Dexamethasone sodium phosphate : 0.08 mg/ml	∅	317
		Heparin sodium : 100 UI/ml Dexmedetomidine : 4 µg/ml	▲	1712
		Heparin sodium : 10000 UI/ml Diatrizoate meglumine : 283 mg/ml	∅	1085
		Heparin sodium Diazepam		3540
		Heparin sodium : 100 UI/ml Diltiazem hydrochloride : 1 mg/ml	◆	4556
		Heparin sodium : 20000 UI/ml Diltiazem hydrochloride : 5 mg/ml	▲	198
		Heparin sodium : 80 >> 10000 UI/ml Diltiazem hydrochloride : 1 & 5 mg/ml	▲	198
		Heparin sodium : 100 UI/ml Diltiazem hydrochloride : 5 mg/ml	◆	4556
		Heparin sodium : 20000 UI/ml Diltiazem hydrochloride : 1 mg/ml	▲	198
		Heparin sodium Dimenhydrinate		2087
		Heparin sodium : 1 UI/ml Diphenhydramine hydrochloride : 50 mg/ml	▲◆	1228
		Heparin sodium : 1 UI/ml Diphenhydramine hydrochloride : 50 mg/ml	RL	1228
		Heparin sodium : 50 UI/ml Dobutamine hydrochloride : 1 mg/ml	∅	317
		Heparin sodium : 100 UI/ml Dobutamine hydrochloride : 2 mg/ml	◆	1041
		Heparin sodium : 100 UI/ml Dobutamine hydrochloride : 4 mg/ml		314
		Heparin sodium : 1 UI/ml Dopamine hydrochloride : 40 mg/ml	▲◆	1228
		Heparin sodium : 50 UI/ml Dopamine hydrochloride : 1.6 mg/ml	∅	317
		Heparin sodium : 1 UI/ml Dopamine hydrochloride : 40 mg/ml	RL	1228
		Heparin sodium : 1000 UI/ml Doxorubicin hydrochloride : 2 mg/ml		763
		Heparin sodium Doxorubicin hydrochloride		3540
		Heparin sodium : 1000 UI/ml Droperidol : 2,5 mg/ml		763
		Heparin sodium : 1 UI/ml Droperidol : 1.25 mg/ml	RL	1228
		Heparin sodium Droperidol		3540
		Heparin sodium : 1 UI/ml Droperidol : 1.25 mg/ml	▲◆	1228
		Heparin sodium : 40 UI/ml Enalaprilate : 0.05 mg/ml	▲	1315
		Heparin sodium : 50 UI/ml Enalaprilate : 0.0125 mg/ml	▲	1703

		Heparin sodium : 1 UI/ml Epinephrine hydrochloride : 100 µg/ml	RL	1228
		Heparin sodium : 1 UI/ml Epinephrine hydrochloride : 100 µg/ml		1228
		Heparin sodium Epirubicin hydrochloride		3632
		Heparin sodium : 1 UI/ml Ergotamine tartrate : 0.5 mg/ml	RL	1228
		Heparin sodium : 1 UI/ml Ergotamine tartrate : 0.5 mg/ml		1228
		Heparin sodium : 50 UI/ml Erythromycin lactobionate : 3.3 mg/ml	∅	317
		Heparin sodium Erythromycin lactobionate		3540
		Heparin sodium : 500 UI/ml Esmolol hydrochloride : 10 mg/ml		3823
		Heparin sodium : 100 UI/ml Fenoldopam mesylate : 80 µg/ml		1803
		Heparin sodium : 1 UI/ml Fentanyl citrate : 50 µg/ml		1228
		Heparin sodium : 1 UI/ml Fentanyl citrate : 50 µg/ml	RL	1228
		Heparin sodium : 50 UI/ml Fluconazole : 2 mg/ml	∅	317
		Heparin sodium : 1000 UI/ml Fluconazole : 2 mg/ml		496
		Heparin sodium : 1 UI/ml Fluorouracil : 50 mg/ml		1228
		Heparin sodium : 1 UI/ml Fluorouracil : 50 mg/ml	RL	1228
		Heparin sodium : 1000 UI/ml Foscarnet sodium : 24 mg/ml	∅	73
		Heparin sodium : 100 UI/ml Furosemide : 10 mg/ml		4724
		Heparin sodium : 500 UI/ml Furosemide : 10 mg/ml		3823
		Heparin sodium : 1 UI/ml Furosemide : 10 mg/ml	RL	1228
		Heparin sodium : 1 UI/ml		1391
		Heparin sodium : 100 UI/ml Cladribine : 0.015 mg/ml		1496
		Heparin sodium : 50 UI/ml Clindamycin phosphate : 12 mg/ml	∅	317
		Heparin sodium : 500 UI/ml		4507
		Heparin sodium : 20,458 >> 28,000 UI/ml		1868
		Heparin sodium : 100 UI/ml Cloxacillin sodium : 100 mg/ml		3012
		Heparin sodium : 100 UI/ml		1415
		Heparin sodium : 208 UI/ml Co-trimoxazole : 3.2/0.64 & 80/16 mg/ml		4254

		Heparin sodium Cytarabine		3580
		Heparin sodium Dacarbazine		3605
		Heparin sodium Dacarbazine		3267
		Heparin sodium Daunorubicin hydrochloride		3604
		Heparin sodium Daunorubicin/cytarabine liposomale : 0,4 mg/mL		4654
		Heparin sodium : 100 UI/ml Diltiazem hydrochloride : 1 mg/ml		314
		Heparin sodium : 10000 UI/ml Dobutamine hydrochloride : 2 mg/ml		1041
		Heparin sodium : 100 UI/ml Dobutamine hydrochloride : 4 mg/ml		295
		Heparin sodium : 100 UI/ml Dobutamine hydrochloride : 2 mg/ml		1352
		Heparin sodium Dobutamine hydrochloride		3540
		Heparin sodium : 40 UI/ml Dobutamine hydrochloride : 1 mg/ml		1058
		Heparin sodium : 100 UI/ml Docetaxel : 0.9 mg/ml		1754
		Heparin sodium : 100 UI/ml Dopamine hydrochloride : 3,2 mg/ml		4389
		Heparin sodium : 187 UI/ml Dopamine hydrochloride : 1,7 >> 3,4 mg/ml		377
		Heparin sodium : 200 UI/ml Dopamine hydrochloride : 0.8 mg/ml		738
		Heparin sodium : 100 UI/ml Dopamine hydrochloride : 3.2 mg/ml		314
		Heparin sodium : 100 UI/ml Doripenem : 5 mg/ml		2262
		Heparin sodium : 1 UI/ml Doxapram hydrochloride : 2 mg/ml		1802
		Heparin sodium Doxorubicin hydrochloride		3645
		Heparin sodium : 1000 UI/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
		Heparin sodium : 50 UI/ml Doxycycline hyclate : 1 mg/ml		317
		Heparin sodium : 45,45 UI/ml Enalaprilate : 0,011 mg/ml		963
		Heparin sodium : 100 UI/ml Epinephrine hydrochloride : 20 µg/ml		314
		Heparin sodium Eptifibatide		3934
		Heparin sodium : 1000 UI/ml Eravacycline : 0,6 mg/ml		4434
		Heparin sodium : 1 UI/ml Ergotamine tartrate : 0.5 mg/ml		1228

		Heparin sodium : 50 & 100 UI/ml Ertapenem : 10 & 20 mg/ml		1906
		Heparin sodium Erythromycin lactobionate		3674
		Heparin sodium : 50 UI/ml Esmolol hydrochloride : 6 mg/ml		174
		Heparin sodium : 40 UI/ml Esmolol hydrochloride : 10 mg/ml		384
		Heparin sodium : 10 UI/ml Ethanol : 70 %		2221
		Heparin sodium : 10 UI/ml Ethanol : 70 %		2221
		Heparin sodium : 1000 UI/ml Ethanol : 70 %		2221
		Heparin sodium : 1000 UI/ml Ethanol : 70 %		2221
		Heparin sodium : 100 UI/ml Etoposide phosphate : 5 mg/ml		1410
		Heparin sodium : 50 UI/ml Famotidine : 0.2 mg/ml		398
		Heparin sodium : 40 UI/ml Famotidine		397
		Heparin sodium : 40 UI/ml Famotidine : 2 mg/ml		215
		Heparin sodium : 100 UI/ml Fentanyl citrate : 50 µg/ml		314
		Heparin sodium : 100 UI/ml Fentanyl citrate : 50 µg/ml		4389
		Heparin sodium : 100 UI/ml Filgrastim : 30 µg/ml		244
		Heparin sodium : 40 >> 1000 UI/ml Fludarabine phosphate : 1 mg/ml		492
		Heparin sodium : 50 UI/ml Flumazenil : 0,02 mg/ml		187
		Heparin sodium : 5 UI/ml Fluorouracil : 0,8 mg/ml		156
		Heparin sodium : 1000 UI/ml Fluorouracil : 50 mg/ml		763
		Heparin sodium : 960 UI/ml Fluorouracil : 24 mg/ml		163
		Heparin sodium : 1000 UI/ml Folate calcium : 10 mg/ml		763
		Heparin sodium : 100 UI/ml Foscarnet sodium : 24 mg/ml		1135
		Heparin sodium : 1000 UI/ml Fosfomicin : 30 mg/ml		4055
		Heparin sodium : 58,34 UI/ml Furosemide : 5,21 mg/ml		1289
		Heparin sodium : 10 UI/ml Furosemide : 10 mg/ml		3210
		Heparin sodium : 500 UI/ml Furosemide : 10 mg/ml		3134

		Heparin sodium : 20 UI/ml Furosemide : 1 mg/ml		1232
		Heparin sodium : 100 UI/ml Furosemide : 10 mg/ml		314
		Heparin sodium : 1000 UI/ml Furosemide : 10 mg/ml		763
		Heparin sodium Furosemide		3465
		Heparin sodium : 1 UI/ml Furosemide : 10 mg/ml		1228
		Heparin sodium : 40 UI/ml Gallium nitrate : 1 mg/ml		91
		Heparin sodium : 100 UI/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Heparin sodium : 10 >> 40 UI/ml Gentamicin sulfate : 4 >> 40 mg/ml		1258
		Heparin sodium Gentamicin sulfate		3520
		Heparin sodium Gentamicin sulfate		3643
		Heparin sodium : 2500 UI/ml Gentamicin sulfate : 3 mg/ml		4612
		Heparin sodium Gentamicin sulfate		3540
		Heparin sodium : 50 UI/ml Gentamicin sulfate : 2 mg/ml		317
		Heparin sodium : 2500 UI/ml Gentamicin sulfate : 4 & 5 mg/ml		4612
		Heparin sodium : 2500 UI/ml Gentamicin sulfate : 1 & 2 mg/ml		4612
		Heparin sodium Gentamicin sulfate		1022
		Heparin sodium : 100 UI/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Heparin sodium : 100 & 200 UI/ml Haloperidol lactate : 5 mg/ml		617
		Heparin sodium : 500 UI/ml		150
		Heparin sodium : 50 UI/ml Glycerophosphate disodium		4332
		Heparin sodium : 500 UI/ml Haloperidol lactate : 0.5 mg/ml		3823
		Heparin sodium Haloperidol lactate		3540
		Heparin sodium : 100 UI/ml Hetastarch : 60 mg/ml		1721
		Heparin sodium Hyaluronidase		3617
		Heparin sodium Hyaluronidase		3540
		Heparin sodium Hyaluronidase		3184

		Heparin sodium : 1 UI/ml Hydralazine hydrochloride : 20 mg/ml	RL	1228
		Heparin sodium : 1 UI/ml Hydralazine hydrochloride : 20 mg/ml		1228
		Heparin sodium Hydrocortisone sodium succinate		3540
		Heparin sodium : 50 UI/ml Hydrocortisone sodium succinate : 2 mg/ml	∅	317
		Heparin sodium : 100 UI/ml Hydrocortisone sodium succinate : 125 mg/ml		132
		Heparin sodium : 100 UI/ml Hydromorphone hydrochloride : 1 mg/ml		314
		Heparin sodium : <12,5 UI/ml Hydromorphone hydrochloride : >25 mg/ml		66
		Heparin sodium : <1 UI/ml Hydromorphone hydrochloride : >10 mg/ml		66
		Heparin sodium : <12,5 UI/ml Hydromorphone hydrochloride : >25 mg/ml		66
		Heparin sodium Hydromorphone hydrochloride : <12.5 mg/ml		66
		Heparin sodium Hydromorphone hydrochloride : <12.5 mg/ml		66
		Heparin sodium : 10 UI/ml Ibuprofen lysinate : 10 mg/ml		4419
		Heparin sodium : 100 UI/ml Ibuprofen lysinate : 10 mg/ml		4419
		Heparin sodium : 100 & 1000 UI/ml Idarubicin hydrochloride : 1 mg/ml		491
		Heparin sodium : 1000 UI/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml		4433
		Heparin sodium : 60 UI/ml Insulin : 0.2 UI/ml		129
		Heparin sodium : 500 UI/ml Insulin : 2 UI/ml		3823
		Heparin sodium : 50 & 400 UI/ml Insulin aspart : 1 UI/ml		1508
		Heparin sodium : 10000 UI/ml Iohexol : 300 mg I/ml	∅	1085
		Heparin sodium : 10000 UI/ml Ioxaglate : 320 mg I/ml	∅	1085
		Heparin sodium : 1000 UI/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Heparin sodium : 1 UI/ml Isoprenaline hydrochloride : 0.2 mg/ml		1228
		Heparin sodium : 1 UI/ml Isoprenaline hydrochloride : 0.2 mg/ml	RL	1228
		Heparin sodium Kanamycin sulfate		3540
		Heparin sodium : 25000 UI/ml Ketamine hydrochloride : 50 mg/ml		2109
		Heparin sodium : 500 UI/ml Labetalol hydrochloride : 4 mg/ml		3823

		Heparin sodium : 40 UI/ml Labetalol hydrochloride : 1 mg/ml		386
		Heparin sodium Labetalol hydrochloride		3540
		Heparin sodium : 100 UI/ml Labetalol hydrochloride : 2 mg/ml		314
		Heparin sodium : 100 UI/ml Labetalol hydrochloride : 5 mg/ml		295
		Heparin sodium : 100 UI/ml Lansoprazole : 0.55 mg/ml		1625
		Heparin sodium : 100 UI/ml Levetiracetam : 100 mg/ml		4108
		Heparin sodium : 208,3 UI/ml Levetiracetam : 15 mg/ml		4698
		Heparin sodium Levofloxacin		3920
		Heparin sodium : 10 UI/ml Levofloxacin : 5 mg/ml		1072
		Heparin sodium Levomopromazine		3540
		Heparin sodium : 100 UI/ml Levosimendan : 2,5 mg/ml		4389
		Heparin sodium : 50 UI/ml Lidocaine hydrochloride : 4 mg/ml		317
		Heparin sodium : 1000 UI/ml Linezolid : 2 mg/ml		1925
		Heparin sodium : 10 >> 10000 UI/ml Linezolid : 0.2 >> 1.92 mg/ml		2057
		Heparin sodium : 100 UI/ml Lorazepam : 0.5 mg/ml		314
		Heparin sodium : 417 UI/ml Lorazepam : 0.33 mg/ml		186
		Heparin sodium : 1 UI/ml Magnesium sulfate : 5 mg/ml	RL	1228
		Heparin sodium : 50 UI/ml Magnesium sulfate : 15.6 mg/ml		2100
		Heparin sodium : 1 UI/ml Magnesium sulfate : 5 mg/ml		1228
		Heparin sodium : 100 UI/ml Melphalan : 0.1 mg/ml		169
		Heparin sodium : 20 UI/ml Meropenem : 1 & 20 mg/ml		266
		Heparin sodium : 1 UI/ml Meropenem : 1 & 50 mg/ml		266
		Heparin sodium : 0.5 UI/ml Meropenem : 0.5 mg/ml	1.5	4180
		Heparin sodium : 0.5 UI/ml Meropenem : 0.5 mg/ml		4180
		Heparin sodium : 0.5 UI/ml Meropenem : 0.5 mg/ml	2.5	4180
		Heparin sodium : 0.5 UI/ml Meropenem : 0.5 mg/ml	4.25	4180

		Heparin sodium : 1000 UI/ml Meropenem : 50 mg/ml		4319
		Heparin sodium : 50 UI/ml Methadone hydrochloride : 0.2 mg/ml		1506
		Heparin sodium : 1000 UI/ml Methotrexate sodium : 25 mg/ml		763
		Heparin sodium Methotrexate sodium		3637
		Heparin sodium : 500 UI/ml Methotrexate sodium : 30 mg/ml		150
		Heparin sodium : 100 UI/ml Methylprednisolone sodium succinate : 5 mg/ml		132
		Heparin sodium : 50 UI/ml Methylprednisolone sodium succinate : 2.5 mg/ml		317
		Heparin sodium : 1000 UI/ml Metoclopramide hydrochloride : 5 mg/ml		763
		Heparin sodium : 1000 UI/ml Metoprolol tartrate : 1 mg/ml		2346
		Heparin sodium : 50 UI/ml Metronidazole : 5 mg/ml		317
		Heparin sodium : 100 UI/ml Micafungin : 1.5 mg/ml		2108
		Heparin sodium : 100 UI/ml Midazolam hydrochloride : 2 mg/ml		314
		Heparin sodium : 100 UI/ml Midazolam hydrochloride : 5 mg/ml		4389
		Heparin sodium : 208,3 UI/ml Midazolam hydrochloride : 1 mg/ml		4698
		Heparin sodium : 417 UI/ml Midazolam hydrochloride : 5 mg/ml		186
		Heparin sodium : 500 UI/ml Midazolam hydrochloride : 2.1 mg/ml		3823
		Heparin sodium : 200 UI/ml Milrinone lactate : 0.8 mg/ml		813
		Heparin sodium : 100 UI/ml Milrinone lactate : 0.2 mg/ml		314
		Heparin sodium : 1 UI/ml Minocycline hydrochloride : 0.2 mg/ml	RL	1228
		Heparin sodium : 1 UI/ml Minocycline hydrochloride : 0.2 mg/ml		1228
		Heparin sodium Mitoxantrone dihydrochloride		3640
		Heparin sodium : 100 & 200 UI/ml Morphine sulfate : 1 >> 10 mg/ml		341
		Heparin sodium : 100 & 200 UI/ml Morphine sulfate : 10 mg/ml		341
		Heparin sodium : 100 & 200 UI/ml Morphine sulfate : 1 >> 5 mg/ml		341
		Heparin sodium Morphine sulfate		3531
		Heparin sodium : 1 UI/ml Morphine sulfate : 15 mg/ml		1228

		Heparin sodium : 100 UI/ml Morphine sulfate : 2 mg/ml		314
		Heparin sodium : 60 UI/ml Morphine sulfate : 1 mg/ml		406
		Heparin sodium : 1 UI/ml Morphine sulfate : 15 mg/ml	RL	1228
		Heparin sodium : 1000 UI/ml N-acetylcysteine : 200 mg/ml	∅	3766
		Heparin sodium : 50 UI/ml Nafcillin sodium : 20 mg/ml	∅	317
		Heparin sodium : 1000 UI/ml Naloxone hydrochloride : 0.4 mg/ml	∅	3408
		Heparin sodium : 208,3 UI/ml Nefopam : 1,7 mg/ml		4698
		Heparin sodium : 1 UI/ml Neostigmine methylsulfate : 0.5 mg/ml	RL	1228
		Heparin sodium : 1 UI/ml Neostigmine methylsulfate : 0.5 mg/ml	 	1228
		Heparin sodium Netilmicin sulfate		3540
		Heparin sodium Netilmicin sulfate		1022
		Heparin sodium Nicardipine hydrochloride		3540
		Heparin sodium : 40 UI/ml Nicardipine hydrochloride : 0.1 mg/ml	 	1490
		Heparin sodium : 100 UI/ml Nicardipine hydrochloride : 1 mg/ml		314
		Heparin sodium : 50 UI/ml Nitroglycerin : 0.2 mg/ml	∅	317
		Heparin sodium : 100 UI/ml Nitroglycerin : 1,6 >> 3,25 mg/ml		295
		Heparin sodium : 500 UI/ml Nitroglycerin : 0.2 mg/ml	 	3823
		Heparin sodium : 100 UI/ml Nitroglycerin : 0.4 mg/ml		314
		Heparin sodium : 50 UI/ml Nitroprusside sodium : 0.2 mg/ml	∅	317
		Heparin sodium : 100 UI/ml Nitroprusside sodium : 0.2 mg/ml		295
		Heparin sodium : 100 UI/ml Norepinephrine bitartrate : 0.128 mg/ml		314
		Heparin sodium Ofloxacin		3562
		Heparin sodium : 40 UI/ml Ondansetron hydrochloride : 1 mg/ml		334
		Heparin sodium : 200 UI/ml Ondansetron hydrochloride : 1.6 mg/ml		1699
		Heparin sodium : 100 UI/ml Oritavancin : 2 mg/ml		3152
		Heparin sodium : 100 UI/ml Oritavancin : 0.8 >>1.2 mg/ml		3152

		Heparin sodium : 100 UI/ml Oxaliplatin : 0,5 mg/ml		1662
		Heparin sodium Oxytetracycline hydrochloride		3540
		Heparin sodium : 100 UI/ml Paclitaxel : 1.2 mg/ml		248
		Heparin sodium : 100 UI/ml		301
		Heparin sodium : 500 UI/ml		939
		Heparin sodium : 208 UI/ml Ornidazole : 31.25 mg/ml		4254
		Heparin sodium : 1 UI/ml Oxacillin sodium : 100 mg/ml	RL	1228
		Heparin sodium : 100 UI/ml		132
		Heparin sodium : 1 UI/ml Oxacillin sodium : 100 mg/ml		1228
		Heparin sodium : 100 UI/ml Palonosetron hydrochloride : 50 µg/ml		2279
		Heparin sodium : 40 UI/ml Pancuronium bromide : 0.05 mg/ml		402
		Heparin sodium Pantoprazole sodium		2090
		Heparin sodium : 1000 UI/ml Paracetamol : 10 mg/ml		4742
		Heparin sodium : 208,3 UI/ml Paracetamol : 10 mg/ml		4698
		Heparin sodium : 100 UI/ml Pemetrexed disodium : 20 mg/ml		1953
		Heparin sodium Penicillin G potassium		3540
		Heparin sodium : 50 UI/ml Penicillin G potassium : 0.04 MUI/ml		317
		Heparin sodium Penicillin G sodium		3540
		Heparin sodium : 100 UI/ml Pentoxifyllin : 5 mg/ml		4538
		Heparin sodium : 60 UI/ml Pethidine hydrochloride : 10 mg/ml		406
		Heparin sodium Pethidine hydrochloride		3525
		Heparin sodium Pethidine hydrochloride		3540
		Heparin sodium : 50 UI/ml Phenytoin sodium : 2 mg/ml		317
		Heparin sodium : 10 & 5000 UI/ml Piperacillin sodium : 40 mg/ml		2037
		Heparin sodium : 50 UI/ml Piperacillin sodium : 60 mg/ml		317
		Heparin sodium : 1.4 UI/ml Piperacillin sodium / tazobactam : 1.38/0.1725 mg/ml		4180
		Heparin sodium : 0.5 UI/ml Piperacillin sodium / tazobactam : 0.5/0.0625 mg/ml		4180

	Heparin sodium : 1.4 UI/ml Piperacillin sodium / tazobactam : 1.38/0.1725 mg/ml		4180	
	Heparin sodium : 1.4 UI/ml Piperacillin sodium / tazobactam : 1.38/0.1725 mg/ml		4180	
	Heparin sodium : 0.5 UI/ml Piperacillin sodium / tazobactam : 0.5/0.0625 mg/ml		4180	
	Heparin sodium : 0.5 UI/ml Piperacillin sodium / tazobactam : 0.5/0.0625 mg/ml		4180	
	Heparin sodium : 0.5 UI/ml Piperacillin sodium / tazobactam : 0.5/0.0625 mg/ml		4180	
	Heparin sodium : 100 UI/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81	
		Heparin sodium : 1000 UI/ml Plazomicin sulfate : 24 mg/ml		4145
	Heparin sodium Polymyxine B		3540	
	Heparin sodium : 58,34 UI/ml Potassium chloride : 1250 mEq/l		1289	
	Heparin sodium : 500 UI/ml Potassium chloride : 10 mEq/l		3823	
	Heparin sodium : 50 UI/ml Potassium chloride : 200 mEq/l		317	
	Heparin sodium Potassium phosphate		3781	
	Heparin sodium : 1 UI/ml Procainamide hydrochloride : 100 mg/ml		1228	
	Heparin sodium : 1 UI/ml Procainamide hydrochloride : 100 mg/ml	RL	1228	
	Heparin sodium : 1 UI/ml Prochlorperazine edysilate : 5 mg/ml		1228	
	Heparin sodium : 1 UI/ml Prochlorperazine edysilate : 5 mg/ml	RL	1228	
	Heparin sodium : 1 UI/ml Promethazine hydrochloride : 50 mg/ml	RL	1228	
	Heparin sodium Promethazine hydrochloride		3540	
	Heparin sodium : 1 UI/ml Promethazine hydrochloride : 50 mg/ml		1228	
		Heparin sodium : 1000 UI/ml Propofol		660
	Heparin sodium : 100 UI/ml Propofol : 10 mg/ml		300	
	Heparin sodium : 1 UI/ml Propranolol hydrochloride : 1 mg/ml	RL	1228	
	Heparin sodium : 1 UI/ml Propranolol hydrochloride : 1 mg/ml		1228	
	Heparin sodium : 100 UI/ml Ranitidine hydrochloride : 1 mg/ml		314	
	Heparin sodium : 10 & 40 UI/ml Ranitidine hydrochloride : 0.05 & 2 mg/ml		214	
	Heparin sodium : 50 UI/ml Ranitidine hydrochloride : 0,5 mg/ml		396	

	Heparin sodium : 50 UI/ml Ranitidine hydrochloride : 1 mg/ml	∅	317
	Heparin sodium : 1000 UI/ml Remdesivir : 1 mg/ml	▲	4768
	Heparin sodium : 100 UI/ml Remifentanyl hydrochloride : 25 & 250 µg/ml	▲	59
	Heparin sodium : 416.7 UI/ml Remifentanyl hydrochloride : 120 µg/ml	◆	3176
	Heparin sodium : 416.7 UI/ml Remifentanyl hydrochloride : 120 µg/ml	◆	3294
	Heparin sodium : 500 UI/ml Remifentanyl hydrochloride : 100 µg/ml	▲	3823
	Heparin sodium Reteplase		3540
	Heparin sodium Reteplase		2212
	Heparin sodium : 1000 UI/ml Salbutamol sulfate : 1 mg/ml	∅	3216
	Heparin sodium : 100 UI/ml Sargramostim : 10 µg/ml	▲	335
	Heparin sodium : 100 UI/ml Sargramostim : 6 §15 µg/ml	▲	891
	Heparin sodium : 1 UI/ml Scopolamine hydrobromide : 0.86 mg/ml	RL	1228
	Heparin sodium : 1 UI/ml Scopolamine hydrobromide : 0.86 mg/ml	▲◆	1228
	Heparin sodium : 1 UI/ml Sildenafil citrate : 0,4 mg/ml	◆	3923
	Heparin sodium Sodium bicarbonate		3466
	Heparin sodium : 500 UI/ml Sodium bicarbonate : 84 mg/ml	▲	3823
	Heparin sodium : 500 UI/ml Sodium bicarbonate : 84 mg/ml	∅	3212
	Heparin sodium : 500 UI/ml Sodium bicarbonate : 14 mg/ml	∅	150
	Heparin sodium : 208 UI/ml Spiramycine adipate : 0.0625 MUI/ml	▲	4254
	Heparin sodium : 100 UI/ml Streptokinase : 30000 UI/ml	◆	92
	Heparin sodium Streptomycin sulfate		3540
	Heparin sodium : 416.7 UI/ml Sufentanyl citrate : 0.005 mg/ml	◆	3294
	Heparin sodium : 1000 UI/ml Sugammadex : 100 mg/ml	∅	3372
	Heparin sodium : 1000 UI/ml Sulbactam/durlobactam : 15/15 mg/ml	▲	4801
	Heparin sodium : 10 UI/ml Tacrolimus : 1000 µg/ml	▲	479
	Heparin sodium : 1000 UI/ml Tedizolid phosphate : 0.8 mg/ml	▲	3827

		Heparin sodium : 10 >> 10000 UI/ml Teicoplanine : 0.02 >> 10 mg/ml		2057
		Heparin sodium : 1000 UI/ml Telavancin hydrochloride : 7,5 mg/ml	 	3254
		Heparin sodium : 1000 UI/ml Telavancin hydrochloride : 7.5 mg/ml	RL	3254
		Heparin sodium : 100 UI/ml Teniposide : 0.1 mg/ml		905
		Heparin sodium : 50 UI/ml Theophylline : 4 mg/ml		317
		Heparin sodium : 1000 UI/ml Thiopental sodium : 25 mg/ml		3767
		Heparin sodium : 100 UI/ml Thiopental sodium : 25 mg/ml		314
		Heparin sodium : 500 UI/ml Thiopental sodium : 60 mg/ml		3823
		Heparin sodium : 100 UI/ml Thiotepa : 1 mg/ml		249
		Heparin sodium : 50 UI/ml Ticarcillin / clavulanic acid : 31 mg/ml		317
		Heparin sodium Tirofiban		1512
		Heparin sodium : 40 & 100 UI/ml Tirofiban : 50 µg/ml	 	1420
		Heparin sodium : 500 UI/ml Tirofiban : 250 µg/ml		3823
		Heparin sodium Tobramycin sulfate		3540
		Heparin sodium : 50 UI/ml Tobramycin sulfate : 0.8 mg/ml		317
		Heparin sodium Triflupromazine hydrochloride		3540
		Heparin sodium : 500 UI/ml Urapidil : 5 mg/ml		3823
		Heparin sodium : 0,5 >> 14,3 UI/ml Vancomycin hydrochloride : 6,9 >> 14,3 mg/ml	 	2375
		Heparin sodium Vancomycin hydrochloride		3540
		Heparin sodium Vancomycin hydrochloride		3588
		Heparin sodium : 5000 UI/ml Vancomycin hydrochloride : 2.5 mg/ml		2037
		Heparin sodium : 100 UI/ml Vancomycin hydrochloride : 0.025 mg/ml		895
		Heparin sodium : 100 UI/ml Vancomycin hydrochloride : 0.025 mg/ml		1414
		Heparin sodium : 10 UI/ml Vancomycin hydrochloride : 2 mg/ml		2037
		Heparin sodium : 50 UI/ml Vancomycin hydrochloride : 6.6 mg/ml		317
		Heparin sodium : 0,5 >> 14,3 UI/ml Vancomycin hydrochloride : 0,015 >> 6,8 mg/ml	 	2375

		Heparin sodium : 10 UI/ml Vancomycin hydrochloride : 0.025 mg/ml		3125
		Heparin sodium : 100 UI/ml Vancomycin hydrochloride : 10 mg/ml		132
		Heparin sodium : 0,5 >> 14,3 UI/ml Vancomycin hydrochloride : 0,015 >> 6,8 mg/ml		2375
		Heparin sodium : 0,5 >> 14,3 UI/ml Vancomycin hydrochloride : 6,9 >> 14,3 mg/ml		2375
		Heparin sodium : 100 UI/ml Vasopressin : 2 & 4 UI/ml		1801
		Heparin sodium : 100 UI/ml Vecuronium bromide : 1 mg/ml		314
		Heparin sodium : 40 UI/ml Vecuronium bromide : 0.1 mg/ml		402
		Heparin sodium : 20 UI/ml Verapamil hydrochloride : 0.08 mg/ml		1057
		Heparin sodium Vinblastine sulfate		3540
		Heparin sodium : 1000 UI/ml Vinblastine sulfate : 1 mg/ml		763
		Heparin sodium : 1000 UI/ml Vincristine sulfate : 1 mg/ml		763
		Heparin sodium : 10 & 100 UI/ml Vinorelbine tartrate : 2 & 3 mg/ml		1070
		Heparin sodium : 100 UI/ml Vinorelbine tartrate : 1 mg/ml		84
		Heparin sodium : 100 UI/ml Vinorelbine tartrate : 1 mg/ml		1070
		Heparin sodium : 208 UI/ml Voriconazole : 8 mg/ml		4254
		Heparin sodium : 100 UI/ml Warfarin sodium : 2 mg/ml		315
		Heparin sodium : 100 UI/ml Zidovudine : 4 mg/ml		337



Voie d'administration



Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.

36	Revue	Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC. Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods. Am J Health-Syst Pharm 1995 ; 52: 2423-2426.
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
66	Revue	Avelar MA, Walker SE. Stability and compatibility of reconstituted hydromorphone with potassium chloride or heparin. Can J Hosp Pharm 1996 ; 49: 140-145.
73	Revue	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
81	Revue	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
91	Revue	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
92	Revue	Lee CY, Mauro VF, Alexander KS. Visual and spectrophotometric determination of compatibility of alteplase and streptokinase with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 606-608.
93	Revue	Hutchings SR, Rusho WJ, Tyler LS. Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery. Am J Health-Syst Pharm 1996 ; 53: 2185-2188.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
129	Revue	Smythe M, Malouf E. Visual compatibility of insulin with secondary intravenous drugs in admixtures. Am J Hosp Pharm 1991 ; 48: 125-126.
132	Revue	Najari Z, Rusho WJ. Compatibility of commonly used bone marrow transplant drugs during Y-site delivery. Am J Health-Syst Pharm 1997 ; 54: 181-184.
150	Revue	Aujoulat P, Coze C, Braguer D, Raybaud C. Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. J Pharm Clin 1993 ; 12: 31-35.
156	Revue	Barberi-Hayob M, Merlin JL, Vigneron M, Conroy T. Addition of heparin in 5-fluorouracil solution for portal vein infusion has no influence on its stability under clinically relevant conditions. Anticancer Drugs 1995 ; 6: 163-164.
163	Revue	Sewell GJ, Allsopp M, Collinson MP, Tyrrell C, Prentice AJ, Copplestone JA. Stability studies on admixtures of 5-fluorouracil with carboplatin and 5-fluorouracil with heparin for administration in continuous infusion regimens. J Clin Pharm Ther 1994 ; 19: 127-133.
169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.

174	Revue	Schaaf LJ, Robinson DH, Vogel GJ, Wulf BG, Drda KD, Moses JO. Stability of esmolol hydrochloride in the presence of aminophylline, bretylium tosylate, heparin sodium, and procainamide hydrochloride. Am J Hosp Pharm 1990 ; 47: 1567-1571.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
186	Revue	Swart EL, Mooren RAG, Van Loenen AC. Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2020-2022.
187	Revue	Olsen KM, Gurley BJ, Davis GA, Christensen R, Monaghan MS. Stability of flumazenil with selected drugs in 5% dextrose injection. Am J Hosp Pharm 1993 ; 50: 1907-1912.
198	Revue	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
214	Revue	Galante LJ, Stewart JT, Warren FW, Edgar JW, Huff AJ. Stability of ranitidine hydrochloride with eight medications in intravenous admixtures. Am J Hosp Pharm 1990 ; 47: 1606-1610.
215	Revue	Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426.
240	Revue	Lam XM, Ward CA, de C du M ^{re} CPR. Stability and activity of alteplase with injectable drugs commonly used in cardiac therapy. Am J Health-Syst Pharm 1995 ; 52: 1904-1909.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
248	Revue	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253	Revue	Trissel LA, Chandler SW, Folstad JT. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2525-2528.
257	Revue	Hunt-Fugate AK, Hennessey CK, Kazarian CM. Stability of fluconazole in injectable solutions. Am J Hosp Pharm 1993 ; 50: 1186-1187.
266	Revue	Patel PR. Compatibility of meropenem with commonly used injectable drugs. Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
288	Revue	Cervenka P, Dejong DJ, Butler BL, Monzingo MD. Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration. Hosp Pharm 1992 ; 27: 957-958,961-962.

289	Revue	Jim LK. Physical and chemical compatibility of intravenous ciprofloxacin with other drugs. Ann Pharmacotherapy 1993 ; 27: 704-707.
295	Revue	Yamashita SK, Walker SE, Choudhury T, Iazzetta J. Compatibility of selected critical care drugs during Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1048-1051.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
314	Revue	Chiu MF, Schwartz ML. Visual compatibility of injectable drugs used in the intensive care unit. Am J Health-Syst Pharm 1997 ; 54: 64-65.
315	Revue	Bahal SM, Lee TJ, McGinnes M, Dobler GL. Visual compatibility of warfarin sodium injection with selected medications and solutions. Am J Health-Syst Pharm 1997 ; 54: 2599-2600.
317	Revue	Kershaw BP, Monnier HL, Mason JH. Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration. Am J Hosp Pharm 1993 ; 50: 1360-1362.
334	Revue	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Revue	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
336	Revue	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
337	Revue	Bashaw ED, Amantea MA, Minor JR, Galleli JF. Visual compatibility of zidovudine with other drugs during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 2532-2533.
341	Revue	Baker DE, Yost GS, Craig VL, Campbell RK. Compatibility of heparin sodium and morphine sulfate. Am J Hosp Pharm 1985 ; 42: 1352-1355.
377	Revue	Pereira-Rosario R, Utamura T, Perrin JH. Interaction of heparin sodium and dopamine hydrochloride in admixtures studied by microcalorimetry. Am J Hosp Pharm 1988 ; 45: 1350-1352.
384	Revue	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 630-632.
386	Revue	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1357-1358.

396	Revue	Chilvers MR, Lysne JM. Visual compatibility of ranitidine hydrochloride with commonly used critical-care medications. Am J Hosp Pharm 1989 ; 46: 2057-2058.
397	Revue	Fong PA, Ward J. Visual compatibility of intravenous famotidine with selected drugs. Am J Hosp Pharm 1989 ; 46: 125-126.
398	Revue	Jay GT, Fanikos J, Souney PF. Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1556-1557.
402	Revue	Savitsky ME. Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 820-821.
406	Revue	Smythe MA, Patel MA, Gasloli RA. Visual compatibility of narcotic analgesics with selected intravenous admixtures. Am J Hosp Pharm 1990 ; 47: 819-820.
479	Revue	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
491	Revue	Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184.
492	Revue	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
496	Revue	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
617	Revue	Solomon DA, Nasinnyk KK. Compatibility of haloperidol lactate and heparin sodium. Am J Hosp Pharm 1982 ; 39: 843-844.
660	Revue	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
738	Revue	Gardella LA, Kesler H, Amann A, Carter JE. Intropin (dopamine hydrochloride) intravenous admixture compatibility. Part 3: Stability with miscellaneous additives. Am J Hosp Pharm 1978 ; 35: 581-584.
763	Revue	Cohen MH, Jonhson-Early A, Hood MA, McKenzie M, Citron ML, Jaffe N, Krasnow SH. Drug precipitation within IV tubing : A potential hazard of chemotherapy administration. Cancer Treat Rep 1985 ; 69: 1325-1326.
791	Revue	Hensrud DD, Buritt MF, Hall LG. Stability of heparin anticoagulant activity over time in parenteral nutrition solutions. JPEN 1996 ; 20: 219-220.
813	Revue	Akkermann SR, Zhang H, Mullins RE, Yaughn K. Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions. Am J Health-Syst Pharm 1999 ; 56: 63-68.
860	Revue	Nelson RW, Young R, Lamnin M. Visual incompatibility of dacarbazine and heparin. Am J Hosp Pharm 1987 ; 44: 2028.

874	Revue	Stiles ML, Allen LV, Mc Laury HJ. Stability of two concentrations of heparin sodium pre-filled in CADD-Micro pump syringes. Int J Pharm Compound 1997 ; 1: 433-434.
891	Revue	Matsuura G. Visual compatibility of sargramostim (GM-CSF) during simulated Y-site administration with selected agents. Hosp Pharm 1992 ; 27: 200, 202, 209.
895	Revue	Yao JDC, Arkin CF, Karchmer AW. Vancomycin stability in heparin and total parenteral nutrition solutions: novel approach to therapy of central venous catheter-related infections. JPEN 1992 ; 16: 268-274.
905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
939	Revue	Gilbar PJ, Groves CF. Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection. Aust J Hosp Pharm 1994 ; 24: 167-170.
963	Revue	Schaaf LJ, Tremel LC, Wulf BG, Vernon KK. Compatibility of enalaprilat with dobutamine, dopamine, heparin, nitroglycerin, potassium chloride and nitroprusside. J Clin Pharm Ther 1990 ; 15: 371-376.
1022	Revue	Hutchinson SMW. Heparin and aminoglycosides instability. Drug Intell Clin Pharm 1986 ; 20: 886.
1041	Revue	Hasegawa GR, Eder JF. Visual compatibility of dobutamine hydrochloride with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 949-951.
1057	Revue	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1058	Revue	Kirschenbaum HL, Aronoff W, Piltz GW, Perentesis GP, Cutie AJ. Compatibility and stability of dobutamine hydrochloride with large-volume parenterals and selected additives. Am J Hosp Pharm 1983 ; 40: 1690-1691.
1067	Revue	Zeidler C, Dettmering D, Schrammel W, Spieteller M. Compatibility of various drugs used in intensive care medicine in polyethylene, PVC and glass infusion containers. EJHP 1999 ; 5: 106-110.
1070	Revue	Balthasar JP. Concentration-dependent incompatibility of vinorelbine tartrate and heparin sodium. Am J Health-Syst Pharm 1999 ; 56: 1891.
1072	Revue	Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA. Compatibility of levofloxacin with 34 medications during simulated Y-site administration. Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1084	Revue	Raupp P, von Kriek R, Schmidt E, Pfahl HG, G?nther O. Incompatibility between fat emulsion and calcium plus heparin in parenteral nutrition of premature babies. Lancet 1988 ; 1(8587): 700.
1085	Revue	Irving HD, Burbridge BE. Incompatibility of contrast agents with intravascular medications. Radiology 1989 ; 173: 91-92.

1135	Revue	Baltz JK, Kennedy P, Minor JR, Gallelli J. Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1990 ; 47: 2075-2077.
1183	Revue	Tunbridge LJ, Lloyd JV, Penhall RK, Wise AL, Maloney T. Stability of diluted heparin sodium stored in plastic syringes. Am J Hosp Pharm 1981 ; 38: 1001-1004.
1228	Revue	Allen LV, Stiles ML. Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2. Am J Hosp Pharm 1981 ; 38: 380-381.
1232	Revue	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1234	Revue	Parkinson R, Wilson JV, Ross M, Denyer SP. Stability of low-dosage heparin in pre-filled syringes. Br J Pharm Pract 1989 ; 11: 34-36.
1258	Revue	Tyler LS, Rehder TL, Davis RB. Effect of gentamicin on heparin activity. Am J Hosp Pharm 1981 ; 38: 537-540.
1289	Revue	Hecq JD, Evrard JM, Gillet P, Grosdent N. Etude de stabilité visuelle du chlorhydrate de chlorpromazine, du chlorure de potassium, de la furosémide et de l'héparine sodique en perfusion continue. Pharmakon 1998 ; 116: 145-148.
1291	Revue	Wright A, Hecker J. Long term stability of heparin in dextrose-saline intravenous fluids. Int J Pharm Pract 1995 ; 3: 253-255.
1315	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1352	Revue	Hasegawa GR, Eder JF. Dobutamine-heparin mixture inadvisable. Am J Hosp Pharm 1984 ; 41: 2588-2589.
1391	Revue	Vanstone GL. Is heparin always compatible with TPN and fat emulsion admixtures? Can J Hosp Pharm 1998 ; 51: 271-272.
1393	Revue	Lyall D, Blythe J. Ciprofloxacin lactate infusion. Pharm J 1987 ; 238: 290.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1414	Revue	Mayer JLR, Pascale VJ, Clyne LP, Malkus H, Santos FS, van Hoff J. Stability of low-dose vancomycin hydrochloride in heparin sodium 100 UI / ml. J Pharm Technol 1999 ; 15: 13-17.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1420	Revue	Bergquist PA, Hunke WA, Reed RA, Manas D, Forsyth RJ, Kenney RR, Cook J, Holahan M. Compatibility of tirofiban HCl with dopamine HCl, famotidine, sodium heparin, lidocaine HCl and potassium chloride during simulated Y-site administration. J Clin Pharm Ther 1999 ; 24: 125-132.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.

1468	Revue	Sautou V, Chopineau J, Gremeau I, Chevrier R, Bruneaux F. Compatibility with medical plastics and stability of continuously and simultaneously infused isosorbide dinitrate and heparin. Int J Pharm 1994 ; 107: 111-119.
1490	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1496	Revue	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1506	Revue	Lopez-Cabezas C, Guerrero L, Molas G, Anglada H, Soy D. Physicochemical compatibility of high concentration drugs usually Y-site administered in intensive care units. EJHP 2015 ;22:107-112.
1508	Revue	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
1512	Laboratoire	Tirofiban (Aggrastat®) - Summary of Product Characteristics Beacon Pharmaceuticals Ltd 2015
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Revue	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1699	Revue	Plaas S, Heck C, Kubrich M. Mischbarkeit von serotonin-antagonisten mit dexamethason und heparin. Krankenhauspharmazie 2000 ; 21: 107-109.
1703	Revue	Schuster F, Bernard R. Kompatibilität von enalaprilat i.v. mit ausgewählten arzneimitteln. Krankenhauspharmazie 1995 ; 16: 101-103.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Revue	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1801	Revue	Feddema S, Rusho WJ, Tyler LS, Barker B. Physical compatibility of vasopressin with medications commonly used in cardiac arrest. Am J Health-Syst Pharm 2003 ; 60: 1271-1272.
1802	Revue	Bell MS, Nolt DH. Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery. Am J Health-Syst Pharm 2003 ; 60: 193-194.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.

1822	Revue	Trissel LA, Seanz C. Physical compatibility of antithymocyte globulin (rabbit) with heparin sodium and hydrocortisone sodium succinate. Am J Health-Syst Pharm 2003 ; 60: 1650-1652.
1868	Revue	Husson E, Crauste-Manciet S, Hadj-Salah E, Segier JC, Broissard D. Stabilité galénique de mélanges commercialisés de nutrition parentérale en présence de médicaments: médicaments dans le mélange. Nutr Clin Metab 2003 ; 17: 8-14.
1906	Revue	McQuade MS, Van Nostrand V, Shariter J, Kanike JD, Forsyth RJ. Stability and compatibility of reconstituted ertapenem with commonly used iv infusion and coinfusion solutions. Am J Health-Syst Pharm 2004 ; 61: 38-45.
1925	Revue	Trissel LA, Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1937	Revue	Lai JJ, Brodeur SK. Physical and chemical stability of daptomycin with nine medications. Ann Pharmacotherapy 2004 ; 38: 1612-1616.
1953	Revue	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1979	Revue	Wu CC, Wang DP, Wong CY, Lin YF. Stability of cefazolin in heparinized and nonheparinized peritoneal dialysis solutions. Am J Health-Syst Pharm 2002 ; 59: 1537-1538.
1982	Revue	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2037	Revue	Robinson JL, Tawfik G, Saxinger L, Stang L, Etches W, Lee B. Stability of heparin and physical compatibility of heparin/antibiotic solutions ... J Antimicrob Chemother 2005 ; 56: 951-953.
2057	Revue	Droste JC, Jeraj HA, MacDonald A, Farrington K. Stability and in vitro efficacy of antibiotic-heparin lock solutions potentially useful for treatment of central venous catheter-related sepsis. J Antimicrob Chemother 2003 ; 51: 849-855.
2087	Revue	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	Revue	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2100	Revue	Gervas S, Gosalbez F. Estabilidad física y química del sulfato magnesico combinado con heparina sodica en solucion salina al 0,9 por 100. Farm Hosp 1995 ; 19: 38-40.
2108	Revue	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2109	Revue	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2212	Laboratoire	Reteplase (Rapilysin®) - Summary of Product Characteristics Actavis UK Ltd 2015

2221	Revue	Cober M.P, Johnson C.E. Stability of 70% alcohol solutions in polypropylene syringes for use in ethanol-lock therapy. Am J Health-Syst Pharm 2007 ; 64, 23: 2480-2482.
2233	Revue	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2247	Revue	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	Revue	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Revue	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2271	Laboratoire	Daptomycine (Cubicin®) Résumé des caractéristiques du produits Novartis 2006
2279	Revue	Kupiec T, Trusley C, Ben M, Trissel LA. Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 18: 1735-1759.
2335	Revue	Canann D, Tyler L.S, Barker B, Condie C. Visual compatibility of i.v. medications routinely used in bone marrow transplant recipients Am J Health-Syst Pharm 2009 ; 66, 8: 727-729
2346	Revue	Newland A.M, Mauro V.F, Alexander K.S. Physical compatibility of metoprolol tartrate injection with selected cardiovascular agents Am J Health-Syst Pharm 2009 ; 66: 986-987.
2375	Revue	Strong DK, Ho W, Nairn JG. Visual compatibility of vancomycin and heparin in peritoneal dialysis solutions Am J Hosp Pharm 1989 ; 46: 1832 - 1833.
3012	Revue	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3125	Revue	Baker D S, Waldrop Bruce, Arnold John. Compatibility and Stability of Cefotaxime, Vancomycin, and Ciprofloxacin in Antibiotic Lock Solutions Containing Heparin. Int J Pharm Compound 2010 ; 14, 4: 346-349.
3134	Revue	Perez Jua En, Maqueda Palau M, Arévalo Rubert Mt, Ribas Nicolau B, Amoros Cerdà SM. Compatibilidad visual y física de la furosemida en mezclas intravenosas para perfusión continua. Enferm Intensiva 2010 ; 21: 96-103.
3152	Revue	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3176	Poster	Humbert Delaloye V, Berger M, Voirol P, Pannatier A. Compatibilité du Remifentanil avec d'autres médicaments injectables : influence du soluté. 16èmes JFSPH, Sion, 18-19 novembre 2010
3184	Laboratoire	Hyaluronidase (Hyalase®) - Summary of Product characteristics.
3210	Revue	Chittabaskara R, Sankar S, Poonam. Compatibility of Parenteral Furosemide with Seventeen Secondary Drugs Used in Standard Concentrations. Int J Pharm Compound 2011 ; 15, 3: 259-261.

3212	Revue	Ribas Nicolau, B.; P?rez Juan, E.; Amor?s Cerd?, S.M.; Ar?valo Rubert, M.J.; Maqueda Palau, M. Compatibilidad f?sica del bicarbonato s?dico con f?rmacos de uso frecuente en la unidad de cuidados intensivos. Enferm Intensiva 2011 ;22:78-82.
3216	Revue	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilit? physique par ?valuation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3249	Revue	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254	Revue	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3267	Laboratoire	Lipomed Laboratories Dacarbazine Lipomed - Summary of Product Characteristics Lipomed 2011
3294	Revue	Humbert-Delaloye V, Berger M, Voirol P, Pannatier A. In vitro compatibility of remifentanil hydrochloride and sufentanil citrate with selected drugs EJHP 2012 ; 19: 57-64.
3327	Revue	LaPlante K.L, Woodmansee S, Mermel L.A. Compatibility and stability of telavancin and vancomycin in heparin or sodium citrate lock solutions. Am J Health-Syst Pharm 2012 ; 69:1405-1409
3372	Revue	Hanci V, Ali Kiraz H, ?m?r D, Ekin S, Uyan B, Yurtlu B.S. Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine. Rev Bras Anesthesiol 2013 ; 63, 1: 163-166.
3408	Revue	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilit? physique de la naloxone avec d'autres m?dicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3463	Revue	Eva Perez Juan, Maria Jos? Ar?valo Rubert , Silvia Monica Amoros Cerda , Palau M.M, Nicolau B.R. F?rmacos en perfusi?n continua en la unidad de cuidados intensivos: estudio de compatibilidad. Nursing 2011 ; 29 :62-6
3464	Revue	Monica Maqueda-Palau, Eva P?rez-Juan, Maria Josep Ar?valo-Rubert, Sylvia Monica Amoros-Cerda, B?rbara Ribas-Nicolau. Compatibilidad f?sica de la amiodarona en perfusi?n continua Enferm Clin 2011 21:25-29.
3465	Revue	E. P?rez Juan, M. Maqueda Palau, M. Ar?valo Rubert, B. Ribas Nicolau, S.M. Amor?s Cerd?. Compatibilidad visual y f?sica de la furosemda en mezclas intravenosas para perfusi?n continua. Enferm Intensiva 2010 ;21:96-103.
3466	Revue	B. Ribas Nicolau, E. P?rez Juan, S.M. Amor?s Cerd?, M.J. Ar?valo Rubert, M. Maqueda Palau. Compatibilidad f?sica del bicarbonato s?dico con f?rmacos de uso frecuente en la unidad de cuidados intensivos Enferm Intensiva 2011 ;22:78-82.
3520	Laboratoire	Cidomycin - Summary of product Characteristics. Sanofi 2011
3525	Laboratoire	Pethidine hydrochloride - Summary of product Characteristics AMCO Amdipharm Mercury 2012
3529	Laboratoire	Ciprofloxacin – Summary of Product Characteristics Hospira 2013
3531	Laboratoire	Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics Wockhardt 2014
3540	Laboratoire	Heparin sodium - Summary of Product Characteristics. Wockhardt 2010
3548	Laboratoire	Cefepime (Maxipime®) - Summary of Product characteristics. Bristol Myers Squibb 2007

3549	Laboratoire	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3562	Laboratoire	Ofloxacin (Tarivid®) - Summary of Product Characteristics Sanofi 2014
3577	Laboratoire	Daunorubicine (Daunoxome®) - Résumé des caractéristiques du produit Galen Limited
3580	Laboratoire	Cytarabine Accord - Résumé des caractéristiques du produit Accord Healthcare France 2016
3588	Laboratoire	Vancomycine (Vancocin®) - Résumé des caractéristiques du produit Sandoz 2011
3604	Laboratoire	Daunorubicine (Cérubidine®) - Résumé des caractéristiques du produit Sanofi Aventis France 2012
3605	Laboratoire	Dacarbazine (Dacarbazine Lipomed®) - Résumé des caractéristiques du produit Lipomed 2010
3616	Laboratoire	Altéplase (Actilyse®) - Résumé des caractéristiques du produit Boehringer Ingelheim 2012
3617	Laboratoire	Hyaluronidase (Hyalase®) - Summary of Product Characteristics Wockhardt 2011
3632	Laboratoire	Epirubicine (Epirubicine Hospira®) - Summary of Product Characteristics Hospira 2017
3637	Laboratoire	Methotrexate (Methotrexate solution for injection®) - Summary of Product Characteristics Hameln Pharmaceuticals 2014
3640	Laboratoire	Mitoxantrone - Summary of Product Characteristics Hospira 2013
3643	Laboratoire	Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015
3645	Laboratoire	Doxorubicin - Summary of Product Characteristics Accord Healthcare 2014
3665	Revue	Ortega R, Salmerón-García A, Cabeza J, Capitán-Vallvey L.F, Navas N. Stability of daptomycin 5 mg/mL and heparin sodium 100 units/mL combined in lactated Ringer's injection and stored in polypropylene syringes at 4 and -20°C. Am J Health-Syst Pharm 2014 ; 71:956-959
3674	Laboratoire	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3687	Laboratoire	Cefuroxime sodium - Summary of Product Characteristics Stravencon 2013
3728	Revue	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3766	Revue	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	Revue	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3781	Revue	Humbert-Delaloye V, Berger-Gryllaki M, Voirol P, Testa B, Pannatier A Screening for physicochemical incompatibilities of intravenous drugs in intensive care units: the case of monobasic potassium phosphate and furosemide. EJHP 2015 ;22:1 56-58

3823	Revue	Juan E.P, Palau M.M, Cerd? S.A, Rubert M.A, Nicolau B.R. Compatibilité physique de médicaments administrés dans l'unité de soins intensifs Pharmactuel 2015 ; 48, 3 : 146-152.
3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftazolidime/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavuquinolone sulfate during simulated Y-site administration. ASHP Midyear 2015
3920	Laboratoire	Levofloxacin - Résumé Caractéristique du Produit Fresenius Kabi 2018
3923	Revue	Luu Y, Thigpen J, Brown S.D. Stability of sildenafil in combination with heparin and dopamine. Am J Health-Syst Pharm 2017 ; 74, 1: e64-e71
3934	Laboratoire	Eptifibatid (Integrilin®) - Résumé des caractéristiques du produit GlaxoSmithKline Laboratoire 2016
3956	Revue	Bastani B; Amin K; Herr A. Prolonged Stability of Stored Vancomycin, Gentamicin, and Heparin for Use in the Antibiotic-Lock Technique. ASAIO Journal 2005 ; 51,6:761-763.
3958	Revue	Henrickson K.J; . Powell K.R; . Schwartz C.L. A Dilute Solution of Vancomycin and Heparin Retains Antibacterial and Anticoagulant Activities . J Infect Dis 1988 ; 157, 3: 600-601.
3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
3976	Revue	Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B. Visual compatibility of blinatumomab with selected co-administered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomicin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4056	Revue	Kandel S, Zaidi S, Wanandy T, Ming L, Castelino R, Sud K, Patel R. Stability of ceftazidime and heparin in four different types of peritoneal dialysis solutions. Perit Dial Int 2017
4108	Revue	Cruz K, Chrchwell M, Mauro V, Boddu. Physical compatibility of levetiracetam injection with heparin, dobutamine, and dopamine. Am J Health-Syst Pharm 2018 ;75;8:510-512
4145	Revue	Asempta T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4166	Revue	Bowie H.M, Haylor V. Stability of heparin in sodium chloride solution. J Clin Pharm Ther 1978 3:211-214



















4180	Revue	Mendes K, Harmanjeet H, Sedeeq M, Modi A, Wanandy T, Zaidi S, Ming L, Castelino R, Sud K, Peterson G, Patel R. Stability of meropenem and piperacillin/tazobactam with heparin in various peritoneal dialysis solutions. Perit Dial Int 2018 ;38,6:430-440
4254	Revue	D'Huart E, Vigneron J, Demoré B. Physical Compatibility of Intravenous Drugs Commonly Used in Intensive Care Units: An Observational Study and Physical Compatibility Laboratory Tests on Anti-Infective Drugs Pharmaceutical Technology in Hospital Pharmacy 2019 ;4,1:29-40
4319	Revue	Lessard J-J, Caron E, Schérier H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4332	Poster	Compatibilité de Glycophos® avec d'autres médicaments administrés en perfusion aux soins intensifs (SI) Compatibilité de Glycophos® avec d'autres médicaments administrés en perfusion aux soins intensifs (SI). JFSPH 2019 2019
4389	Revue	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédomidine, le lévamisentan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4419	Revue	Holt R.J, Siegert S.W.K, Krishna A. Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection. J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161.
4433	Revue	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4434	Revue	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4491	Revue	De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pilar P, De Miguel M, Campino A. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. Eur J Pediatr 2020
4507	Revue	Ross E, Salinas A, Petty K, Her C, Carpenter J. Compatibility of medications with intravenous lipid emulsions: Effects of simulated Y-site mixing. Am J Health-Syst Pharm 2020 ;77,23:1980-1985
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4538	Revue	Campbell A, Petrovski M, Senarathna G, Mukadam ,Strunk T, Batty K. Compatibility of pentoxifylline and parenteral medications. Archives of Disease in Childhood 2020 ; 105: 395-397.
4556	Revue	Dobson, S.R, Mauro, V.F, Boddu, S.H.S, Churchwell, M.D. The Physical Compatibility of Clinically Used Concentrations of Diltiazem Hydrochloride With Heparin Sodium. J Pharm Technol 2020 ; 36, 4: 126-129.
4603	Revue	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4612	Revue	Villaba-Moreno AM, Gil-Navarro MV, Cotrina-Luque J, Pérez-Moreno MA, Chamorro-de Vega E. Estabilidad de la solución de gentamicina y heparina para sellado de catéter. OFIL 2014 24;2:86-90
4651	Revue	De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pascual P, De Miguel M, Campino A. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. Eur J Pediatr 2021 ;180,1169–1176.

4654	Poster	Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R. Compatibilité visuelle du Vyxeos® lors d'administration en Y avec une sélection de médicaments injectables. Communication personnelle 2021
4698	Revue	Ayari G, Huart E, Vigneron J, Demoré B. Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs. Pharmaceutical Technology in Hospital Pharmacy 2022
4724	Revue	Maktabi B, Howard MS, Baki G, Churchwell MD Intravenous Physical Compatibility of Heparin Sodium and Furosemide. Int J Pharm Compound 2022 ;26,6:522-526
4732	Revue	Kenneally A, Agbana P, Gardner B, Bae Y, Mitchell T, Beckman E. Compatibility of calcium chloride with milrinone, epinephrine, vasopressin, and heparin via in vitro testing and simulated Y-site administration. Am J Health-Syst Pharm 2023 80, 3;164-170
4742	Revue	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4768	Revue	Kondo M, Genpei M, Watanabe K, Yoshida M, Tagui N, Fukao S, Sugaya K, Takase H. Y-site injection physical compatibility of remdesivir with select intravenous drugs used in palliative care and for treating coronavirus disease 2019. Journal of Nippon Medical school 2023
4801	Revue	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:



Dictionnaire

	Anticoagulant		Injectable
	Noms commerciaux		Stabilité des solutions
	Contenant		Molécule
	Concentration		Température
	Conservation		Durée de stabilité
	Biosimilaire		Données conflictuelles
	Bibliographie		Verre
	Chlorure de sodium 0,9%		Lumière
	Jour		Polyvinyl chlorure
	NaCl 0,9% ou glucose 5%		Non précisée
	Glucose 5%		Polyéthylène
	A l'abri de la lumière		Heure
	Seringue polypropylène		Aucun
	Non précisé		Stabilité en mélange
	Solvant		Molécule
	Dianéal® PD1 1.5% glucose (Baxter)		Dianéal® PD2 4.25% glucose (Baxter)
	Dianéal® PD2 2.5% glucose (Baxter)		Extraneal® (Baxter)
	Physionéal® 1.36 (Baxter)		Physionéal® 2.27 (Baxter)
	Physionéal® 3.86 (Baxter)		Polypropylène
RL	Ringer lactate		Facteur influençant la stabilité
	Nutrition parentérale (mélange ternaire)		Provoque
	Dégradation		Nutrition parentérale (mélange binaire)
	Adsorption		Compatibilités
	Compatible		Précipitation immédiate
	Incompatible		Eau pour préparation injectable
	Précipitation en 24 heures		Incompatibilité non précisée
	Turbidité immédiate		Précipitation en 30 minutes
	Instabilité de l'émulsion immédiate		Dianéal® PD2 1.5% glucose (Baxter)
	Instabilité chimique		Changement de couleur
	NaCl 0,9% + bactériostatique		Précipitation en 4 heures

 Précipitation en 5 heures	 Changement de couleur à 6 heures
 Précipitation en 1 heure	 Eau ppi + bactériostatique
 NaHCO ₃	 Solvant spécifique
 Turbidité en 4 heures	 Dianéal® 1.5% glucose (Baxter)
 Dianéal® 2.5% glucose (Baxter)	 Dianéal® 4.25% glucose (Baxter)
 Dégagement gazeux	 Instabilité de l'émulsion en 1 heure
 Dianéal® PD1 4.25% glucose (Baxter)	 Voie d'administration
 Intraveineuse	 Perfusion continue
 Bibliographie	 Dictionnaire